Alaunos Therapeutics faces a critical existential threat as its cash reserves have dwindled to $354,000, representing a near-total depletion from the $6.1 million held in 2023Q4. The company lacks a functional commercial engine, with revenue effectively at zer...
Price trend, volume and key moving averages
Trailing total returns as of 9/25/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 14, 2026 | -$0.41 vs — | — vs — |
Q2 2026 May 15, 2026 | -$0.59 vs — | — vs — |
Q2 2026 Mar 31, 2026 | -$0.40+89.1% vs -$3.69 | $3,000+0.0% vs $3,000 |
Q4 2025 Nov 14, 2025 | -$0.55+88.8% vs -$4.90 | — vs — |
Alaunos Therapeutics announces pricing of a public offering of common stock and pre-funded warrants to fund working capital and general corporate purposes.
Shares of Alaunos Therapeutics Inc (NASDAQ:TCRT) rose sharply in pre-market trading following a Securities and Exchange Commission filing that showed the company approved and adopted its Second Amended and Restated By-Laws, effective immediately.
Benchmark TCRT against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Alaunos Therapeutics, Inc. (TCRT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.13 | $2.76M | -0.51 | -50% | -83520% | -198.1% | — | |
| $10.80 | $4.82B | -9.91 | 60.6% | -89.09% | -40.51% | — | |
| $2.33 | $271.58M | -2.03 | -51.24% | -1941.09% | -65.08% | — | |
| $0.35 | $45.35M | -0.35 | 266.65% | -1655.35% | -108.72% | — | |
| $34.00 | $7.02B | -12.27 | — | -7585.86% | -69.59% | — | |
| $115.81 | $9.53B | -31.38 | -16.72% | -285.41% | -21.5% | — |
Alaunos Therapeutics, Inc. (TCRT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Alaunos Therapeutics, Inc. (TCRT) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jun 29, 2026·SEC
May 26, 2026·SEC
May 18, 2026·SEC
Get notified when TCRT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Alaunos Therapeutics, Inc. (TCRT) stock FAQ — growth, dividends, profitability & financials explained
Alaunos Therapeutics, Inc. (TCRT) reported $0.0M in revenue for fiscal year 2025. This represents a 74% increase from $0.0M in 2001.
Alaunos Therapeutics, Inc. (TCRT) saw revenue decline by 50.0% over the past year.
Alaunos Therapeutics, Inc. (TCRT) reported a net loss of $4.0M for fiscal year 2025.
Alaunos Therapeutics, Inc. (TCRT) has a return on equity (ROE) of -198.1%. Negative ROE indicates the company is unprofitable.
Alaunos Therapeutics, Inc. (TCRT) had negative free cash flow of $2.8M in fiscal year 2025, likely due to heavy capital investments.
